Drugs / GNR-069
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05492409 | Mar 2022 → Apr 2024 | autoimmune thrombocytopenic purpura | AO GENERIUM | Completed | No outcome recorded |
| Phase 3 | NCT05220878 | Sep 2021 → Aug 2023 | autoimmune thrombocytopenic purpura | AO GENERIUM | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNR-069 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05220878 ↗ |
| Modality | Protein / enzyme biologic | “Biological: GNR-069” NCT05220878 ↗ |
| Route | Subcutaneous | “multiple weekly subcutaneous injections of GNR-069” NCT05220878 ↗ |